On March 15, 2023 AB Science SA (Euronext – FR0010557264 – AB) reported that it will host a live webcast on Thursday March 16, 2023, from 6pm to 7pm CET, to present the ongoing phase 1/2 with AB8939 and its synthetic microtubule destabilizer agents (MDA) platform (Press release, AB Science, MAR 15, 2023, View Source [SID1234628810]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This live webcast will provide further details on:
The pharmacological properties of AB8939 and its key differentiating factors
The therapeutic potential of AB8939, demonstrated through a series of preclinicalexperiments
The ongoing Phase 1/2 study and the first case report from the initial stage of this study

The following attendees will participate to the live webcast:
Alain Moussy, co-founder and CEO of AB Science
Olivier Hermine, MD, PhD, Head of the hematological department at the Necker-Enfants Malades hospital, Paris, France
Christian Auclair, PhD, expert in onco-pharmacology
Laurent Gros, PhD, Head of Drug Discovery of AB Science The presentation will be followed by a Q&A session with the management of AB Science. Dial-In & Webcast Information Webcast date: Thursday, March 16, 2023. US: 1pm-2pm ET; Europe: 6pm-7pm CET Dial in numbers to listen the live webcast:
Dial in number for the US: +1 646 722 4916 Dial in number for France: +33 1 72 72 74 03
Dial in number for countries outside US and France: Numbers for other countries are listed on the webcast page
Conference ID: 42846282#